Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK's Largest Retailer
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ: COSM) has announced a significant expansion of its retail presence in the UK with the introduction of its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4%, at Tesco, the country's largest retailer. This strategic move is poised to enhance the visibility and accessibility of C-Scrub, tapping into Tesco's extensive nationwide store network and robust online platform, which serves millions of customers weekly and holds nearly 30% of the market share in the UK.
C-Scrub is designed to effectively reduce bacteria and support skin hygiene, making it a valuable product in preventing infections. With its recent listing on Tesco.com, Cosmos Health aims to capitalize on the market momentum in the UK, signaling a crucial step in the company’s growth strategy. CEO Greg Siokas remarked on the pivotal nature of this placement, highlighting that its partnership with Tesco not only increases C-Scrub’s market presence but also enhances the company’s credibility. He emphasized that this milestone lays a foundation for the potential rollout of additional products in the future, reinforcing Cosmos Health's position in both the UK and the broader European markets.
Founded in 2009 and headquartered in Nevada, Cosmos Health is a diversified global healthcare group, focusing on innovative pharmaceuticals, nutraceuticals, and telehealth services. The company operates under stringent manufacturing standards in Europe and is actively expanding its presence across Europe, Asia, and North America, showcasing a commitment to addressing major health issues through research and development.
This announcement represents a significant advancement for Cosmos Health as it seeks to leverage established relationships with major retailers to foster continued growth.
MWN-AI** Analysis
Cosmos Health Inc. (NASDAQ: COSM) has made a significant move by launching its antimicrobial skin cleanser, C-Scrub, through Tesco, the UK's largest retailer. This partnership not only enhances the product's visibility but also strengthens Cosmos Health's foothold in the competitive UK market, where Tesco commands nearly 30% market share.
The listing of C-Scrub in Tesco's extensive network can be viewed as a pivotal moment for Cosmos Health, aligning with CEO Greg Siokas's vision of expanding their retail presence. The collaboration with a trusted retailer like Tesco could spark increased consumer confidence and demand for C-Scrub, which is well-positioned as a reliable antiseptic wash amidst growing health hygiene concerns, particularly post-pandemic.
Investors should be attentive to this expansion as it represents a substantial growth opportunity. Expansion through established retail channels like Tesco not only enhances revenue prospects but also paves the way for future product rollouts in the UK and broader European markets. Cosmos Health’s strategy to secure partnerships with leading retailers also indicates a robust pipeline for its portfolio, including pharmaceuticals and nutraceuticals.
However, potential investors should remain cautious of the inherent risks, particularly those associated with regulatory compliance and market competition. Cosmos Health operates in a highly regulated industry, and any setback in product approvals or market penetration can significantly affect performance. The company's diverse product range and strategic focus on R&D partnerships exemplify a forward-thinking approach, but monitoring developments is crucial.
In summary, the partnership with Tesco is a noteworthy development that may accelerate revenue growth for Cosmos Health in the UK. With a promising outlook for C-Scrub and a strong retail ally, COSM could present an attractive investment opportunity, albeit with careful consideration of the associated risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Tesco, the UK’s largest retailer.
Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailers globally, generating over $80 billion in annual revenue. In the UK, Tesco is the clear market leader, holding nearly 30% market share and serving millions of customers weekly through its extensive nationwide store network and robust online platform.
Expanding distribution through this established and trusted retail platform represents a meaningful advancement in Cosmos Health’s UK growth strategy and significantly enhances C-Scrub’s visibility, accessibility, and market credibility.
C-Scrub Listed on Tesco.com
C-Scrub is a powerful antiseptic wash offering reliable skin disinfectant properties. It is designed to reduce bacteria and help prevent infection, supporting effective skin hygiene. Cosmos Health expects continued momentum for C-Scrub in the UK as it further strengthens retail partnerships and expands its distribution footprint.
Greg Siokas, CEO of Cosmos Health, stated: “C-Scrub’s entry into Tesco represents a pivotal moment for Cosmos. Building on our established online presence with Amazon, securing placement with the UK’s largest retailer significantly enhances our retail presence and strengthens our credibility in the market. Beyond the immediate growth opportunity for C-Scrub, this milestone establishes a powerful platform for the potential rollout of additional products from our portfolio over time, further solidifying our position in the UK and across broader European markets.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4f55c572-5957-454e-81d1-fb1cb2a0ee0d
FAQ**
How does the expansion of Cosmos Holdings Inc. COSM into Tesco impact its competitive positioning within the UK healthcare retail market?
What specific growth strategies does Cosmos Holdings Inc. COSM plan to implement following the introduction of C-Scrub in Tesco?
Can Cosmos Holdings Inc. COSM leverage its online presence to drive sales for C-Scrub in addition to its retail launch at Tesco?
What challenges does Cosmos Holdings Inc. COSM foresee in maintaining its retail momentum with C-Scrub given the competitive landscape in UK healthcare products?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Holdings Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
-5.83% G/L:
$0.365 Last:
204,195 Volume:
$0.3811 Open:
